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ZUSAMMENFASSUNG 
In den letzten Jahren wurden wiederholt Vertreter einer neuen Klasse von 
psychostimulierenden Designerdrogen, den so genannten Pyrrolidinophenonen, 
sichergestellt. Dies ist als Teil eines Trends anzusehen durch gezielte chemische 
Abwandlung von Betäubungsmitteln oder deren Leitstrukturen neue Designerdrogen 
zu synthetisieren, die nicht mehr der Betäubungsmittelgesetzgebung unterliegen. 
Solche neuen Designerdrogen sind in der Regel nicht auf mögliche Nebenwirkungen 
oder Toxizität untersucht und bergen daher ein unbekanntes Gefährdungspotential 
für die Konsumenten. Um dieses abschätzen zu können, sind Untersuchungen zum 
Stoffwechsel dieser neuen Drogen erforderlich, wofür Referenzsubstanzen der 
gebildeten Hauptmetaboliten benötigt werden. 
Das Ziel der vorliegenden Arbeit war die biotechnologische Synthese, die 
Isolierung und Aufreinigung von Stoffwechselprodukten zweier Pyrrolidinophenone. 
Die 4’-Hydroxymethyl-Metaboliten der Designerdrogen 4’-Methyl-α-pyrrolidinopropio-
phenon und 4’-Methyl-α-pyrrolidinohexanophenon wurden unter Verwendung der 
Spalthefestämme CAD64, welcher humane Cytochrom-P450-Reduktase und das 
humane Cytochrom P450 Isozym CYP2D6 exprimiert, und CAD66, welcher humane 
Cytochrom-P450-Reduktase und humanes CYP2C19 exprimiert, synthetisiert. Nach 
Inkubation mit den entsprechenden Muttersubstanzen konnten die entstandenen 
Produkte, 4’-Hydroxymethyl-α-pyrrolidinopropiophenon und 4’-Hydroxymethyl-α-
pyrrolidinohexanophenon aus den jeweiligen Hefekulturen durch Festphasen-
extraktion isoliert, mittels semipräparativer Hochleistungsflüssigkeitschromatographie 
von verbleibender Muttersubstanz und Matrixbestandteilen getrennt, durch eine 
Flüssig-flüssig-Extraktion aus dem Fließmittel extrahiert und in Form ihrer 
Hydrochloride ausgefällt werden. Die Identität der synthetisierten Produkte konnte 
mittels Gaschromatographie-Massenspektrometrie und Magnetresonanz-Spektro-
skopie bestätigt werden. Zudem ergab die Analyse mittels Hochleistungs-
flüssigkeitschromatographie mit UV-Detektion  eine hohe Reinheit der Produkte. 
In dieser Arbeit konnte gezeigt werden, dass die biotechnologische Synthese der 
beiden Pyrrolidinophenon-Metaboliten eine Alternative zur klassisch-chemischen 
Mehrstufensynthese darstellt und im Vergleich zu dieser zeitsparender und sicherer 
im Hinblick auf den geringeren Einsatz gefährlicher Chemikalien ist.  
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SUMMARY 
Over the last years the police repeatedly seized substances belonging to a new 
class of psychostimulant designer drugs, the so-called pyrrolidinophenones. This can 
be seen as part of a trend to circumvent the law for controlled substances by 
specifically changing the chemical structure of certain drugs of abuse. These newly 
created substances have usually never been studied towards possible side effects or 
toxicity in humans and are therefore of unknown risk for the consumers. For 
assessing the latter, studies on the metabolism of these new drugs are necessary for 
which reference substances of the main metabolites are needed.  
The aim of the presented study was the biotechnological synthesis, isolation and 
clean-up of the metabolites of new designer drugs belonging to the group of 
pyrrolidinophenones. The 4’-hydroxymethyl metabolites of the designer drugs 
4’-methyl-α-pyrrolidinopropiophenone and 4’-methyl-α-pyrrolidinohexanophenone 
were synthesized using the fission yeast strains CAD64, co-expressing human 
cytochrome P450 reductase and human cytochrome P450 isozyme CYP2D6, and 
CAD66, co-expressing human cytochrome P450 reductase and CYP2C19. After 
incubation with the respective parent drugs, the metabolites, 4’-hydroxymethyl-α-
pyrrolidinopropiophenone and 4’-hydroxymethyl-α-pyrrolidinohexanophenone, were 
isolated from the yeast cultures by solid-phase extraction. Using high-performance 
liquid chromatography they were then separated from remaining parent drug and 
matrix compounds to be extracted from the mobile phase by liquid-liquid extraction. 
Finally, the metabolites could be precipitated as hydrochloric salts. The identity of the 
synthesized metabolites was confirmed using gas chromatography-mass 
spectrometry and magnetic resonance spectroscopy. Moreover, high product purity 
was proven by high-performance liquid chromatography with UV detection. 
The present study shows that the biotechnological synthesis of drug metabolites is 
an alternative to classical chemical multi-step synthesis and in comparison to the 
latter more time-saving and safer regarding the reduced use of hazardous chemicals 
and reaction conditions.  
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1 INTRODUCTION 
1.1 GENERAL ASPECTS OF DESIGNER DRUGS 
The appearance of ever new psychoactive compounds on the illicit or grey drug 
market has become an increasing challenge for authorities and toxicologists in 
Germany and elsewhere in the world. These substances are usually derived from 
established drugs of abuse by more or less significant modifications of their chemical 
structure in illegal private laboratories in order to circumvent the controlled 
substances laws and/or to optimize the pharmacological properties of the respective 
drugs. During the last two decades a huge number of new drugs from various drug 
classes have emerged on the illicit drug market all over the world. Only some of 
these compounds have meanwhile been scheduled as controlled substances. The 
majority is still sold as so-called ‘legal highs’ via the internet (Europe) or can even be 
purchased locally in independent stores (USA) [35,45]. New designer drugs have 
never been systematically studied towards their potential hazardous effects on the 
human organism. Hence, there is only little or no information on potential signs of an 
overdose or side effects of these compounds, especially when they first appear on 
the market. Also, because of their unknown structure and metabolism there are no 
standardized methods to prove their presence in biological samples during 
toxicological screening procedures. Thus, dealing with an intoxicated patient the 
presence of a new designer drug responsible for possible clinical symptoms 
presented may be overlooked. 
 
1.2 PYRROLIDINOPHENONES, HISTORY AND METABOLISM 
The so-called pyrrolidinophenones are one class of these new designer drugs that 
have appeared in form of tablets and powders on the illicit drug market in Germany 
[37]. The chemical structures of the pyrrolidinophenones are schown in Scheme 1. 
α-Pyrrolidinopropiophenone (PPP) [37,47] is the pyrrolidinophenone-type drug with 
the simplest structure and all others can be considered as PPP derivatives with an 
elongated side chain such as α-pyrrolidinovalerophenone (PVP), with a substituted 
aromatic ring such as 4'-methyl-α-pyrrolidinopropiophenone (MPPP) [37,46,47], 4'-
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methoxy-α-pyrrolidinopropiophenone (MOPPP) [48], 3',4'-methylenedioxy-α-
pyrrolidinopropiophenone (MDPPP) [37,49], or with an elongated side-chain and a 
substituted  aromatic ring such as 4'-methyl-α-pyrrolidinobutyrophenone (MPBP) 
[32,55] and 4'-methyl-α-pyrrolidinohexanophenone (MPHP) [51,55]. Most recently, a 
ring substituted analogue of PVP, namely 3,4-methylenedioxypyrovalerone (MDPV), 
which is also seen as a synthetic cathinone derivative, has been described in the 
literature [23,28,31,56]. The route of application of these drugs varies. Oral ingestion, 
snorting, smoking, and inhalation as well as sublingual, intravenous, intramuscular, 
or rectal administration have been reported. They have further been taken in 
combination with other drugs, such as alcohol, beta-blockers, or cannabis to either 
reduce harmful effects or enhance desired effects [6]. For MDPV, limited prevalence 
data are available that suggest a considerable popularity of this drug among drug 
users [23,45]. For all other pyrrolidinophenones, there are no reliable data on the 
frequency of their abuse which may be due to the fact that the presence of 
pyrrolidinophenones and their metabolites might have been overlooked in routine 
drug screenings, because specific analytical methods are required for their detection 
in urine samples [32,34, 46,47,48,49,51]. 
 
Scheme 1 Chemical structures and acronym names of pyrrolidinophenone-type drugs. 
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It can be assumed that due to structural similarities the pharmacological properties 
of the pyrrolidinophenones are similar to the psychostimulant pyrovalerone [4'-
methyl-α-pyrrolidinovalerophenone]. This assumption can particularly be made for 
the 4’-methyl substituted compounds MPPP, MPBP, MPHP and MDPV. Pyrovalerone 
acts by release [13,40] and reuptake inhibition [27] of dopamine and norepinephrine. 
The psychostimulant effects of pyrovalerone are similar to those of amphetamine, but 
pyrovalerone has less influence on the motor system [18,20,52]. Pyrovalerone was 
marketed as a therapeutic drug in the 1960ies and 1970ies [15,19,44], but was later 
scheduled as a controlled substance after reports of intravenous abuse [7]. In an 
internet research performed by Coppola et al. MDPV was evaluated towards 
psychostimulant effects described by drug users. Reported motivations for using 
MDPV were increased concentration, prolonged sexual performance, increased 
sociability, energy and euphoria at low doses. At high doses psychostimulant effects 
were referred to as stronger than those of cocaine or amphetamines [6]. Thus, the 
assumed similar pharmacologic profile of other pyrrolidinophenone-type designer 
drugs would certainly explain their abuse potential [34].  
Also the reported adverse effects and clinical symptoms can be assumed to be 
similar within the group of pyrrolidinophenones. For MDPV and MPHP mainly 
neurological, cardiovascular and psychopathological symptoms have been 
described, such as: tachycardia, hypertension, hyperthermia, hallucinations, 
paranoia, aggressive behaviour, liver damage, rhabdomyolysis and consecutive 
kidney damage, even leading to necessity of intensive care treatment [6,39].  
It has been shown in various animal species, that the main metabolic pathway of 
the 4’-methyl substituted pyrrolidinophenones MPPP [47], MPBP [33], pyrovalerone 
[25,30,41,42] and MPHP [51] was hydroxylation of the 4’-methyl groups with 
subsequent oxidation to the respective carboxylic acids as shown in Scheme 2. For 
pyrovalerone, this was also the main metabolic pathway in a human subject [30]. In 
vitro the 4’-hydroxymethyl metabolite of pyrovalerone is also a potent inhibitor of 
dopamine and norepinephrine transporters [27], although with a lower potency than 
that of its parent drug. The respective 4’-carboxy metabolite of pyrovalerone was 
found to be inactive in vivo [30]. A recently published case report by Sauer et al. of 
acute poisoning due to MPHP further supports the assumption of similar metabolic 
pathways as only the 4’-carboxy metabolite was detected in urine samples of the 
patient [39].  
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Scheme 2 Main metabolic pathway of the 4’-methyl substituted pyrrolidinophenones MPPP, MPBP, 
pyrovalerone and MPHP. The initial rate limiting step is a P450 catalyzed hydroxylation of the 
4’-methyl group that is followed by oxidation of the resulting alcohol to the corresponding carboxylic 
acid. 
 
In consideration of their structural similarity to pyrovalerone, the 4’-hydroxymethyl 
metabolites of MPPP, MPBP and MPHP can also be expected to be 
pharmacologically active. In the main metabolic pathway of these drugs their 
formation seems to be the rate limiting step. To enable pharmacologic and 
toxicologic risk assessment of these drugs in human beings it is essential to fully 
understand their metabolic pathways [34]. 
  
1.3 HUMAN CYTOCHROME P450 
Cytochrome P450 mono-oxygenases (P450s) were first described in 1958. They 
were found to be ubiquitous proteins that account for oxidation of numerous 
compounds, such as steroids, prostaglandins and fatty acids. They are also the 
major enzymes involved in human drug metabolism for more than 90% of oxidative 
metabolic reaction of xenobiotics are catalyzed by P450s [16]. So far we know about 
57 human P450 isozymes of which 15 have been proven to be responsible for 
metabolism of xenobiotics. These are P450s 1A1, 1A2, 2A6, 2A13, 2B6, 2C8, 2C9, 
2C18, 2C19, 2D6, 2E1, 2F1, 3A4, 3A5 and 3A7 [16]. Due to polymorphisms in the 
genes coding for some CYP450s (e.g. P450s 2C9, 2C19 and 2D6) there is an inter-
individual variability of enzyme composition leading to pharmacokinetically distinct 
subpopulations and subsequently to individual alteration of efficacy and toxicity of 
drugs [29]. Also there are different drugs and food ingredients which, when co-
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ingested, can lead to enzyme inhibition or induction resulting in reduction or 
enhancement of the activity of P450s. In order to enable realistic risk assessment of 
increased side effects in poor metabolizers information about the involvement of 
human P450 enzymes in the 4’-methyl hydroxylation is needed, especially with 
regard to pharmacogenetic and drug/drug or drug/food interactions. 
 
1.4 SCHIZOSACCHAROMYCES POMBE 
Schizosaccharomyces pombe is a fission yeast first isolated in East African millet 
beer in 1893 by Lindner [24]. The name derives from the Swahili word for beer 
“pombe”. It is an ancient species diverged from baker’s yeast around 400 million 
years ago. S. pombe is a eukaryote with structures and processes similar to those 
encountered in higher eukaryotes [3,14,21,22,38]. Its genome sequence is 
completely known and genetic techniques for working with this species are well 
established [1,57]. These are good reasons why S. pombe seems to be a suitable 
organism for heterologous expression of microsomal human P450s involved in drug 
metabolism. Also fission yeast was found to have only two putative endogenous 
P450s by homology which significantly decreases the risk for unwanted side reaction 
leading to biased results [57]. Finally, it has already been described to successfully 
express mitochondrial human P450s [4,9-11], microsomal human P450s [12, 33, 58] 
and for biotechnological synthesis of drug metabolites [12,33,34] . 
 
1.5 BIOTECHNOLOGICAL SYNTHESIS OF DRUG METABOLITES 
To enable measurement of involvement of human P450s in MPPP and MPHP 
4’-methyl-hydroxylation and pharmacologic activity of the resulting metabolites 
4’-hydroxymethyl-α-pyrrolidinopropiophenone (HO-MPPP) and 4’-hydroxymethyl-α-
pyrrolidinohexanophenone (HO-MPHP), a reference standard of these metabolites is 
needed. Currently there is no such reference standard commercially available. There 
have been descriptions of how to chemically synthesize the corresponding metabolite 
of pyrovalerone using classical chemical synthesis [30]. This would involve eight 
different steps with an expected overall yield of metabolite of approximately 30%. 
Studies reported were able to show that biotechnological synthesis of drug 
metabolites using human P450 isozymes heterologously expressed in S. pombe is a 
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versatile alternative to the rather complicated classical chemical multi-step synthesis 
[12,33,34]. As model drug MPBP was used and P450 2D6 heterologously expressed 
in S. pombe strain CAD 58 served as model enzyme. By biotechnological synthesis 
approximately 40 mg of 4’-hydroxymethyl-α-pyrrolidinophenone (HO-MPBP) were 
obtained with a purity greater than 98%. Following this successful approach new 
fission yeast strains have been constructed, that heterologously co-express human 
P450 reductase (hCPR) and either P450 2B6, P450 2C9, P450 2C19, P450 2D6, or 
P450 3A4 [12,34]. 
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1.6 AIM OF THE STUDY 
The aim of the present study was to synthesize the drug metabolites HO-MPPP 
and HO-MPHP by applying the concept of biotechnological synthesis of drug 
metabolites using one of the newly constructed S. pombe fission yeast strains co-
expressing hCPR and human CYP450s.  
 
The following approach was used: 
• Incubation of the designer drugs MPPP and MPHP with S. pombe strains 
CAD64 (hCPR + CYP2D6) or CAD66 (hCPR + CYP 2C19) under defined 
conditions 
• Extraction of drug metabolites and remaining parent drug from incubation 
supernatant using solid-phase extraction (SPE) 
• Separation of drug metabolite and remaining parent drug from incubation 
matrix compounds using semi-preparative high-performance liquid 
chromatography (HPLC) 
• Isolation of drug metabolite from HPLC fractions using liquid-liquid extraction 
(LLE) 
• Precipitation of the purified metabolite products as hydrochloric salts 
• Structure confirmation and purity check of the final products by HPLC-UV, 
gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic 
resonance spectroscopy (NMR). 
 
 
 
  10 
2 MATERIALS AND METHODS 
2.1 CHEMICALS AND REAGENTS 
MPPP·HCl and MPHP·HNO3 were provided by the Hessian State Criminal Office 
(Wiesbaden, Germany) for research purposes. The purity and identity had been 
proven by mass spectrometry, infrared spectroscopy and 1H-NMR. The S. pombe 
strains CAD64 (co-expressing CYP2D6 and hCPR) and CAD66 (co-expressing 
CYP2C19 and hCPR) were cloned and characterized by PomBiotech (Saarbrücken, 
Germany). Varian Bond Elut SCX HF cartridges (5 g, 20 mL) were obtained from 
Varian (Darmstadt, Germany). N-Methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) 
was obtained from Fluka (Steinheim, Germany). All other chemicals and 
biochemicals used were obtained from Merck (Darmstadt, Germany) and were of 
analytical grade. 
 
2.2 BIOMASS PRODUCTION 
Cells from permanent cultures of the respective strains were streaked on 
Edinburgh minimal media (EMM) dishes containing 0.01 % leucine (w/v) and 5 µM 
thiamine and grown for 3 days at 30 °C. Cell materi al from the plates was transferred 
to a 10 mL EMM preculture with 0.01 % leucine (w/v) in absence of thiamine. All 
subsequent cultures were grown in absence of thiamine to keep the nmt1 promoter 
controlling heterologous enzyme expression in an active state. Biomass production 
was scaled up by factor 10 to yield 100 mL or 1000 mL cell suspensions in batch 
cultures. Usually, the final cell density was around 5 × 107 cells/mL with cells being in 
the stationary growth phase. After biomass production, the cells were centrifuged at 
3000 × g for 5 min except for 1000 mL cultures where centrifugation was carried out 
at 5000 × g for 25 min. The biomass was washed three times with cold, deionized 
water and finally re-suspended in 0.1 M phosphate buffer (pH 8). 
 
 
 
 
 
  11 
2.3 BIOTECHNOLOGICAL SYNTHESIS OF DRUG METABOLITES 
2.3.1 Biotechnological Synthesis of HO-MPPP  
2.3.1.1 Incubation of MPPP with CAD64 
At first the substrate MPPP·HCl (63.4 mg, 250 µmol) was added to 1.0 L of CAD64 
cell suspension (1.2 × 108 cells/mL) in 0.1 M phosphate buffer (pH 8) containing 2% 
glucose (w/v). The mixture was incubated in a 2 L Erlenmeyer flask at 30 °C over 
48 h at a shaking velocity of 150 rpm. In-process control samples (100 µL) were 
drawn at time points 0 h, 9 h, 24 h, 36 h and 48 h and analyzed by HPLC-UV as 
described below. After 48 h, concentrated H3PO4 was added to a final pH of 3.5, the 
incubation mixture was then shaken for another 30 min at 150 rpm. Thereafter, it was 
centrifuged (8000 × g, 30 min) and the supernatant was used for further workup. 
 
2.3.1.2 Extraction of MPPP and HO-MPPP 
Four Bond Elut SCX HF cartridges (5 g, 20 mL) were put on a VacMaster10 
vaccum manifold (Separtis; Grenzach-Wyhlen, Switzerland) and each conditioned 
with 20 mL of methanol and 20 mL of water. Thereafter, one quarter of the incubation 
supernatant was passed through each of the four cartridges under reduced pressure. 
The passed through supernatant from all four columns was combined and collected 
in 100 mL fractions. After the supernatant had completely been passed through, each 
cartridge was washed with two times 20 mL of 0.1 M HCl and the passed through 
washing solutions were collected and combined. Then each cartridge was washed 
twice with 20 mL of methanol and the passed through washing solvents were 
collected and combined. Finally, the retained compounds were eluted thrice with 
40 mL of methanol-concentrated aqueous ammonia (96:4 v/v) per cartridge. The 
eluates of each elution step were collected and combined. In-process control 
samples of the 100 mL supernatant fractions and the washing solvents were directly 
analyzed by HPLC-UV as described below. A sample (100 µL) of each eluate fraction 
was evaporated to dryness (56 °C) and reconstituted  in 250 µL HPLC solvent prior to 
analysis. 
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2.3.1.3 Separation using semi-preparative HPLC 
The combined eluates of the first and second elution step were evaporated to 
dryness (70 °C, reduced pressure). The residue was reconstituted in 8 mL of 50 mM 
ammonium formate buffer (pH 3.5)/acetonitrile (60:40 v/v). Aliquots (250 µL) were 
injected into the semi-preparative HPLC system consisting of a Hewlett Packard (HP) 
1050 series injector (Agilent Technologies, AT; Waldbronn, Germany) equipped with 
a 1.0 mL loop, an AT 1200 series G1361A preparative pump, and an AT 1100 series 
diode array detector. The stationary phase was an AT Zorbax-300 SCX column 
(9.4 × 250 mm, 5 µm). The isocratic mobile phase consisted of 50 mM ammonium 
formate buffer (pH 3.5)/acetonitrile (80:20 v/v) delivered at a flow rate of 15 mL/min. 
The diode array detection range was from 190 nm to 900 nm with a target 
wavelength of 265 nm. After the first injection, all fractions with significant peaks at 
265 nm were collected. The fractions containing HO-MPPP and MPPP were 
collected and combined with the corresponding fractions. 
 
2.3.1.4 Isolation and Precipitation of HO-MPPP and MPPP 
From the combined fractions of the semi-preparative HPLC containing either 
HO-MPPP or MPPP acetonitrile was removed by evaporation (70 °C, reduced 
pressure). NaOH (1 M) was added to the remaining aqueous part to a final pH of 12 
and the solution was twice extracted with 200 mL of ethyl acetate using a 1000 mL 
separating funnel. Before and after each extraction step a sample of the aqueous 
phase was analyzed by HPLC-UV. After extraction, the organic phases were 
combined, dried over anhydrous Na2SO4, and subsequently evaporated to dryness 
(70 °C, reduced pressure). The residue was reconsti tuted in 5 mL of dry ethyl acetate 
and transferred to a 15 mL reaction tube. After adding one drop of 10 M HCl, the tube 
was sealed, vigorously shaken for 1 min, and left in the refrigerator over night. The 
next day, the tube was centrifuged (10,000 × g, 5 min) and the supernatant was 
removed. The precipitated product was washed twice with 1 mL of ethyl acetate and 
dried (75 °C, reduced pressure). 
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2.3.2 Biotechnological Synthesis of HO-MPHP  
2.3.2.1 Incubation of MPHP with CAD64 and CAD66 
At first the substrate MPHP·HNO3 (80.5 mg, 250 µmol) was added to 1.0 L of 
CAD64 cell suspension (1.2 × 108 cells/mL) in 0.1 M phosphate buffer (pH 8) 
containing 2% glucose (w/v). The mixture was incubated in a 2 L Erlenmeyer flask at 
30 °C over 66 h at a shaking velocity of 150 rpm. I n-process control samples 
(0.5 mL) were drawn at time points 0 h, 17.5 h, 41 h, and 66 h and analyzed by 
HPLC-UV as described below. After 66 h, concentrated H3PO4 was added to a final 
pH of 3.5, the incubation mixture was then shaken for another 30 min at 150 rpm. 
Thereafter, it was centrifuged (8000 × g, 30 min) and the supernatant was used for 
further workup. 
In a second approach the substrate MPHP·HNO3 (80.5 mg, 250 µmol) was added 
to 1.0 L of CAD66 cell suspension (1.2 × 108 cells/mL) in 0.1 M phosphate buffer (pH 
8) containing 2% glucose (w/v). The mixture was incubated in a 2 L Erlenmeyer flask 
at 30 °C over 48 h at a shaking velocity of 150 rpm . After 48 h, concentrated H3PO4 
was added to a final pH of 3.5, the incubation mixture was then shaken for another 
30 min at 150 rpm. Thereafter, it was centrifuged (8000 x g, 30 min) and the 
supernatant was used for further work up. 
 
2.3.2.2 Extraction of MPHP and HO-MPHP 
Four Bond Elut SCX HF cartridges (5 g, 20 mL) were put on a VacMaster10 
vaccum manifold (Separtis; Grenzach-Wyhlen, Switzerland) and each conditioned 
with 20 mL of methanol and 20 mL of water. Thereafter, one quarter of the 
supernatant of the incubation of MPHP with CAD64 was passed through each of the 
four cartridges under reduced pressure. The passed through supernatant from all 
four columns was combined and collected in 100 mL fractions. After the supernatant 
had completely been passed through, each cartridge was washed with two times 
20 mL of 0.1 M HCl and the passed through washing solutions were collected and 
combined. Thereafter, each cartridge was washed twice with 20 mL of methanol and 
the passed through washing solvents were collected and combined. Finally, the 
retained compounds were eluted thrice with 40 mL of methanol-concentrated 
aqueous ammonia (96:4 v/v) per cartridge. The eluates of each elution step were 
collected and combined. In-process control samples of the 100 mL supernatant 
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fractions and the washing solvents were directly analyzed by HPLC-UV as described 
below. A sample (100 µL) of each eluate fraction was evaporated to dryness (56 °C) 
and reconstituted in 250 µL HPLC solvent prior to analysis. The supernatant of the 
incubation of MPHP with CAD66 was worked up accordingly. 
 
2.3.2.3 Separation using semi-preparative HPLC 
The combined eluates of the first and second elution step were evaporated to 
dryness (70 °C, reduced pressure). The residue was reconstituted in 8 mL of 50 mM 
ammonium formate buffer (pH 3.5)/acetonitrile (60:40 v/v). Aliquots (250 µL) were 
injected into the semi-preparative HPLC system consisting of a Hewlett Packard (HP) 
1050 series injector (Agilent Technologies, AT; Waldbronn, Germany) equipped with 
a 1.0 mL loop, an AT 1200 series G1361A preparative pump, and an AT 1100 series 
diode array detector. The stationary phase was an AT Zorbax-300 SCX column 
(9.4 × 250 mm, 5 µm). The isocratic mobile phase consisted of 50 mM ammonium 
formate buffer (pH 3.5)/acetonitrile (80:20 v/v) delivered at a flow rate of 15 mL/min. 
The diode array detection range was from 190 nm to 900 nm with a target 
wavelength of 263.5 nm. After the first injection, all fractions with significant peaks at 
263.5 nm were collected. The fractions containing HO-MPHP were collected and 
combined. 
 
2.3.2.4 Isolation and Precipitation of HO-MPHP 
From the combined fractions of the semi-preparative HPLC acetonitrile was 
removed by evaporation (70 °C, reduced pressure). N aOH (1 M) was added to the 
remaining aqueous part to a final pH of 12 and the solution was twice extracted with 
250 mL of ethyl acetate using a 1000 mL separating funnel. Before and after each 
extraction step a sample of the aqueous phase was analyzed by HPLC-UV. After 
extraction, the organic phases were combined, dried over anhydrous Na2SO4, and 
subsequently evaporated to dryness (70 °C, reduced pressure). The residue was 
reconstituted in 5 mL of dry ethyl acetate and transferred to a 15 mL reaction tube. 
After adding one drop of 37 M HCl, the content of the tube was evaporated to 
dryness and reconstituted in methanol. The liquid was then again partially 
evaporated and the tube filled up with ethyl acetate. Then the tube was sealed, 
vigorously shaken for 1 min, and left in the refrigerator over night.  The next day, the 
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tube was centrifuged (10,000 × g, 5 min) and the supernatant was removed. The 
precipitated product was washed twice with 1 mL of ethyl acetate and dried (75 °C, 
reduced pressure). 
 
2.4 IDENTITY, STRUCTURE CONFIRMATION AND PURITY TESTS  
2.4.1 Identity confirmation  
Approximately 1 mg of product was dissolved in 1mL methanol. For identity 
confirmation by GC-MS, 100 µL of this solution were transferred to an autosampler 
vial and evaporated to dryness under a stream of nitrogen at 56 °C. The residue was 
reconstituted in 50 µL of ethyl acetate. After adding 50 µL of MSTFA the vial was 
sealed and derivatization was carried out for 5 min using microwave irradiation at 
440 W. The sample was then diluted with 900 µL of ethyl acetate. Aliquots (3 µL) 
were subsequently analyzed by GC-MS in the electron ionization (EI) and positive-
ion chemical ionization (PICI) mode. 
 
2.4.2 Structure confirmation  
For structural confirmation by NMR, solutions of MPPP·HCl and MPHP·HNO3 and 
their respective products were prepared in CD3OD (HO-MPPP 5 mg/mL, HO-MPHP 
10 mg/mL). 1H-NMR (500 MHz) and 13C-NMR spectra (125 MHz) were recorded on a 
Bruker DRX 500 (Bruker, Rheinstetten, Germany) at 300 K. The chemical shifts were 
given in δ values (ppm) relative to the solvent peaks at δH 3.30 and δC 49.00. 
 
2.4.3 Purity tests 
For purity check, 1 mg of product was dissolved in 1 mL of 50 mM ammonium 
formate buffer (pH 3.5)/acetonitrile (80:20 v/v) and 20 µL subsequently analyzed by 
HPLC-UV with conditions described below. Purity was determined as the percentage 
of the product peak area of the total peak area. 
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2.5 ANALYSIS BY HPLC-UV AND GC-MS  
2.5.1 HPLC-UV analysis 
2.5.1.1 Apparatus 
A HP 1050 series HPLC system consisting of a quaternary pump, a degasser, an 
autosampler and a UV/vis detector operated at λ = 265 nm was used.  
2.5.1.2 HPLC Conditions 
All in-process control samples and the purity check sample were analyzed using an 
injection volume of 20 µL. The stationary phase was an AT Zorbax 300-SCX column 
(2.1 × 150 mm, 5 µm) and the isocratic mobile phase consisting of 50 mM ammonium 
formate buffer (pH 3.5)/acetonitrile (80:20 v/v) was delivered at a flow rate of 
1.2 mL/min.  
 
2.5.2 GC-MS analysis 
2.5.2.1 Apparatus 
Analysis for the trimethylsilylated sample extracts of the initial experiments and the 
trimethylsilylated final products, HO-MPPP and HO-MPHP respectively, was carried 
out using a HP 5890 Series II GC system combined with an HP 5989B MS Engine 
mass spectrometer and an HP MS ChemStation (DOS series) with HP G1034C 
software. 
2.5.2.2 GC-MS conditions 
The GC conditions were as follows: splitless injection mode; column, HP-1 capillary 
(12 m x 0.2 mm I.D.), cross linked methylsilicone, 330 nm film thickness; injection 
port temperature, 280 °C; carrier gas, helium; flow -rate 1 mL/min; column 
temperature, programmed from 100-310°C at 30°/min, initial time 3 min, final time 8 
min. The MS conditions were as follows: full scan mode, m/z 50-550 u; EI: ionization 
energy, 70 eV; PICI: ionization energy, 230 eV; ion source temperature, 220 °C; 
capillary direct interface heated at 260 °C. 
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3 RESULTS 
3.1 BIOTECHNOLOGICAL SYNTHESIS OF DRUG METABOLITES 
3.1.1 Biotechnological Synthesis of HO·MPPP 
3.1.1.1 Incubation of MPPP with CAD64 
As shown in Figure 1 in the in-process control samples there was an increase of 
the metabolite peaks between 0 h and 36 h, but no further increase was observed 
between 36 h and 48 h. The amount of parent compound decreased continuously 
until 48 h, but remained still in considerable abundance. 
 
Figure 1 Peak areas of MPPP and HO-MPPP in HPLC-UV analysis (see 2.5.1) of in-process control 
samples taken during incubation of MPPP with CAD64. 
 
3.1.1.2 Extraction of MPPP and HO-MPPP 
Prior to the passage through the extraction cartridges supernatant samples were 
taken for HPLC-UV analysis. In comparison to HO-MPPP peaks in supernatant 
samples after the passage the extraction loss of HO-MPPP was negligible in the first 
100 mL fraction and increased to approximately 20 % in the last fraction, resulting in 
total extraction loss over all fractions of about 10 %. Only very minor amounts of 
HO-MPPP were washed from the cartridges during washing steps. During elution the 
vast majority (about 90 %) of HO-MPPP could be eluted in the first elution fraction. 
The second fraction was found to only contain traces of HO-MPPP (<0.5 %).  
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3.1.1.3 Separation using semi-preparative HPLC 
Baseline separation of HO-MPPP from co-extracted matrix compounds and parent 
drug MPPP was achieved within 15 min, the injection volume being 250 µL. This is 
illustrated in Figure 2. 
 
 
Figure 2 Chromatogram of semi-preparative HPLC cleanup of solid-phase extract reconstituted in 
8 mL of HPLC solvent (injection volume, 250 µL). It can be seen that the HO-MPPP peak eluting at 4.0 
min was baseline separated from matrix compounds and untransformed parent drug MPPP eluting at 
6.0 min. 
 
 
3.1.1.4 Isolation and Precipitation of HO·MPPP and MPPP 
HPLC-UV analysis of the combined fractions from semi-preparative HPLC before 
and after each extraction step with ethyl acetate showed that a large percentage of 
HO-MPPP had already been extracted with the first extraction step. After the second 
extraction step detection of HO-MPPP was no longer detectable in the aqueous 
phase. Addition of concentrated HCl to the reconstituted organic extracts led to a 
milky suspension. Leaving the suspension in the refrigerator over night resulted in 
the formation of fine crystals. After centrifugation, removal of the supernatant, 
washing of the precipitate, and drying, the final product was obtained as an off-white 
crystalline powder. The yield was approximately 10 mg which corresponds to 
37 µmol of HO-MPPP·HCl or 14.8 % of the theoretical maximum yield for the entire 
process. However, considering that only about 40 % of the initial MPPP were 
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biotransformed to HO-MPPP, this shows that the extraction and purification process 
gave a yield of 40 % of the metabolite present in the supernatant after incubation.  
Also, in analogous preparation of the fractions from semi-preparative HPLC 
containing the parent drug MPPP, 4 mg of MPPP were obtained. This corresponds to 
18.43 µmol and therefore about 7.5 % of the initial amount of added drug. 
 
3.1.2 Biotechnological Synthesis of HO-MPHP 
3.1.2.1 Incubation with of MPHP with CAD64 and CAD66 
The parent compound MPHP and (trimethylsilylated) HO-MPHP could be identified 
in the supernatants of both strains. However, in the CAD64 sample, the peak 
corresponding to HO-MPHP was considerably more abundant and that of the parent 
drug in comparison to the CAD66 sample. Additionally, in the CAD66 incubation, 
minor amounts of a MPHP metabolite hydroxylated at the hexanone moiety and of 
two isomeric MPHP metabolites hydroxylated at the 4’-methyl and the hexanone 
moiety could be detected. Only the incubation supernatant of CAD 64 was worked up 
further. 
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 Figure 3 Peak areas of MPHP and HO-MPHP in HPLC-UV analysis (see 2.5.1) of in-process control 
samples taken during incubation of MPHP with CAD64. 
 
As shown in Figure 3, the metabolite peaks in the in-process control samples of the 
incubation with CAD64 increased between 0 h and 41 h, but did not further increase 
between 41 h and 66 h. At the same time, the peak of the parent compound 
decreased to almost zero at 41 h and had entirely disappeared at 66 h. Apart from 
the peaks of the parent drug and the target metabolite, additional peaks were 
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observed at approximately 0.6 min and at 1.2 min both of which continuously 
increased with incubation time. The peak eluting at 0.6 min was also observed in 
MPHP-free CAD64 incubations and can be attributed to fission yeast matrix. The 
peak eluting at 1.2 min was absent in MPHP-free incubations and therefore most 
likely attributable to an unknown MPHP metabolite.  
 
3.1.2.2 Extraction of MPHP and HO-MPHP 
Comparison of the HO-MPHP peaks in supernatant samples taken before and after 
passage through the extraction cartridges showed that the extraction loss of 
HO-MPHP was about 0.1 % in the first 100 mL fraction and increased to 
approximately 4 % in the last fraction. Total extraction loss over all fractions was 
approximately 1.3 %. During the washing steps only very minor amounts HO-MPHP 
were washed from the cartridges. During elution, the largest amount (about two 
thirds) of HO-MPHP was eluted in the first elution fraction. The second fraction still 
contained approximately one third of HO-MPHP, while only traces (<0.5 %) were 
found in the third elution fraction. 
 
3.1.2.3 Separation using semi-preparative HPLC 
As illustrated in Figure 4, baseline separation of HO-MPHP from co-extracted 
matrix compounds and the peak of the potential unknown metabolite was achieved 
within 10 min. The injection volume of 250 µL proved to be a good compromise 
between the total number of injections into semi-preparative HPLC and overload 
effects on the column. 
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. Figure 4. Chromatogram of semi-preparative HPLC cleanup of solid-phase extract reconstituted in 
8 mL of HPLC solvent (injection volume 250 µL). It can be seen that the HO-MPHP peak eluting at 
4.0 min was baseline separated from a presumed minor metabolite eluting at 2.3 min and from matrix 
compounds. 
 
 
3.1.2.4 Isolation and precipitation of HO-MPHP 
HPLC-UV analysis of the combined fractions from semi-preparative HPLC before 
and after each extraction step with ethyl acetate showed that a large percentage of 
HO-MPHP had already been extracted after the first extraction step. After the second 
extraction step, HO-MPHP was no longer detectable in the aqueous phase. Addition 
of concentrated HCl to the reconstituted organic extracts led to a milky suspension 
that cleared over night under formation of fine crystals. After centrifugation, removal 
of the supernatant, washing of the precipitate, and drying, the final product was 
obtained as an off-white crystalline powder. The yield was 42 mg which corresponds 
to 138 µmol of HO-MPHP·HCl or 55% of the theoretical maximum yield. 
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3.2 IDENTITY, STRUCTURE CONFIRMATION AND PURITY TESTS 
3.2.1 Identity confirmation 
3.2.1.1 Identity confirmation of HO-MPPP 
The fragments of the EI mass spectrum proved to be in full agreement with 
chemical structure of trimethylsilylated HO-MPPP. The abundant signal at m/z 306 
with the typical adduct ions at m/z 334 and m/z 346 in the PICI mass spectrum are in 
line with [M+H]+, [M+C2H5]+, and [M+C3H5]+ of trimethylsilylated HO-MPPP confirming 
its molecular mass. The EI and PICI mass spectra of HO-MPPP are shown in 
Figure 5. No further relevant peaks were observed by GC-MS. 
 
 
. Figure 5. EI (top) and PICI (bottom) mass spectra of trimethylsilylated HO-MPPP. 
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3.2.2.2 Identity confirmation of HO-MPHP 
The fragments of the EI mass spectrum proved to be in full agreement with 
chemical structure of trimethylsilylated HO-MPHP. The abundant signal at m/z 348 
with the and typical adduct ions at m/z 376 and m/z 388 in the PICI mass spectrum 
are in line with [M+H]+, [M+C2H5]+, and [M+C3H5]+ of trimethylsilylated HO-MPHP 
confirming its molecular mass. The EI and PICI mass spectra of HO-MPPP are 
shown in Figure 6. No further relevant peaks were observed by GC-MS.  
 
 
 
Figure 6. EI (top) and PICI (bottom) mass spectra of trimethylsilylated HO-MPHP. 
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3.2.2 Structure Confirmation  
3.2.1.1 Structure confirmation of HO-MPPP 
Figure 7 shows the 1H-NMR spectra of the parent drug MPPP·HCl (top) and the 
isolated metabolite HO-MPPP·HCl (bottom) recorded during this study. Comparing 
these spectra, it can be seen that the three proton singlet at δH 2.45 ppm present in 
the spectrum of the parent drug has disappeared in the spectrum of the metabolite 
while a new singlet corresponding to two protons has appeared at δH 4.72 ppm. 
These findings are in exact agreement with the structure of HO-MPHP. 
 
 
 
 
Figure 7. 1H-NMR spectra of MPPP·HCl (top) and HO-MPHP·HCl (bottom). The labeling of the 
positions of the chemical structures corresponds to the labeling of proton signals in the respective 
panels. The shift of the three proton signal of the 4’-methyl group of MPPP at δH 2.45 ppm to a two 
proton signal at δH 4.72 ppm in the spectrum of HO-MPPP confirms the chemical structure of the 
latter. 
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3.2.2.2 Structure confirmation of HO-MPHP 
Figure 8 shows the 1H-NMR spectra of the parent drug MPHP·HNO3 (top) and the 
isolated metabolite HO-MPHP·HCl (bottom) recorded during this study. Comparing 
these spectra, it can be seen that the three proton singlet at δH 2.45 ppm present in 
the spectrum of the parent drug has disappeared in the spectrum of the metabolite 
while a new singlet corresponding to two protons has appeared at δH 4.72 ppm. This 
is accompanied by a downfield shift of the respective 13C signals from δC 21.78 
(MPHP·HNO3) to δC 64.31 (HO-MPHP·HCl) (data not shown). These findings are in 
exact agreement with the structure of HO-MPHP. 
 
 
 
Figure 8. 1H-NMR spectra of MPHP·HNO3 (top) and HO-MPHP·HCl (bottom). The labeling of the 
positions of the chemical structures corresponds to the labeling of proton signals in the respective 
panels. The shift of the three proton signal of the 4’-methyl group of MPHP at δH 2.45 ppm to a two 
proton signal at δH 4.72 ppm in the spectrum of HO-MPHP confirms the chemical structure of the 
latter. 
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3.2.3 Purity tests 
3.2.3.1 Purity test for HO-MPPP 
With the cation-exchange Zorbax 300-SCX column the peak area of the product 
peak accounted for about 93 % of total peak area. The respective HPLC 
chromatogram is shown in Figure 9. 
 
 
Figure 9. Chromatograms of a 1 mg/mL solution of the isolated product HO-MPPP·HCl on Zorbax 
300-SCX column (2.1 × 150 mm, 5 µm), 50 mmol/L ammonium formate buffer (pH 3.5)/acetonitrile 
(80:20 v/v) delivered at 1.2 mL/min. The injection volume was 20 µL and UV detection was performed 
at 265 nm. The HO-MPPP peak accounted for about 93% of total peak area. 
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3.2.3.2 Purity test for HO·MPHP 
With the cation-exchange Zorbax 300-SCX, the peak area of the product peak 
accounted for more than 99 % of total peak area. The respective HPLC 
chromatogram is shown in Figure 10. 
 
 
 
Figure 10. Chromatogram of a 1 mg/mL solution of the isolated product HO-MPHP·HCl on Zorbax 
300-SCX column (2.1 × 150 mm, 5 µm), 50 mmol/L ammonium formate buffer (pH 3.5)/acetonitrile 
(80:20 v/v) delivered at 1.2 mL/min. The injection volume was 20 µL and UV detection was performed 
at 265 nm. The HO-MPHP peak accounted for more than 99% of total peak area. 
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4 DISCUSSION 
The aim of the presented work was the biotechnological synthesis, isolation and 
purification of HO-MPPP and HO-MPHP, the metabolites of the new 
pyrrolidonophenone-type designer drugs MPPP and MPHP, respectively, and to 
therefore prove the feasibility of biotechnological synthesis of drug metabolites using 
microsomal human P450s heterologously expressed in the fission yeast S. pombe. 
The metabolites were needed as reference substance for studies on the quantitative 
involvement of human P450 isozymes in the main metabolic pathways of these drugs 
in humans. Moreover, they would be available for  studies on the 
pharmacologic/toxcologic characterization of the metabolite as required by a recent 
guidance document of the US Food and Drug Administration for certain metabolites 
of therapeutic drugs [34,54]. 
The biotechnological synthesis of the drug metabolites as described here has 
several advantages over their classical chemical synthesis according to the protocol 
for the synthesis of the corresponding hydroxymethyl metabolite of the 
pyrrolidinophenone homologue pyrovalerone [30]. Enzyme catalyzed 4’-methyl-
hydroxylation of MPPP and MPHP is only one step process while chemical synthesis 
involves eight different synthetic steps.  In case of MPHP the total reaction time of 
both biotechnological and chemical synthesis is similar with 66 h and 62 h, 
respectively [34]. The total reaction time for biotechnological synthesis of HO-MPPP 
is even significantly lower with 48 h. Apart from that, chemical synthesis would have 
involved the time-consuming setup of more or less complicated chemical reaction 
apparatus as well as isolation, cleanup, and characterization of intermediate 
products. In contrast, biotechnological synthesis was performed in a simple 
Erlenmeyer flask and isolation and cleanup had to be performed only once. The 
synthetic protocol as described by Michaelis et al. would further have involved 
aggressive reaction conditions, such as refluxing of methanol with continual passage 
of HCl gas. Also the use of hazardous reagents and solvents, such as CuCN, CHCl3, 
benzene, CaC2 or Br2 was necessary [30]. In contrast, the biotechnological synthesis 
ran smoothly at 30 °C and only comparatively non-ha zardous chemicals and 
reagents were used for isolation and cleanup of the products.  
To enable biotechnological synthesis the knowledge of main metabolic pathways of 
the respective drugs is essential. For MPPP and MPHP these metabolic pathways 
are already described in the literature [46,47,50,51]. In both cases 4’-methyl-
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hydroxylation with subsequent oxidation to the respective carboxylic acid was the 
main metabolic pathway in the rat [46,51] and the formation of the 4’-methyl-hydroxy-
metabolite can be assumed to be the initial reaction in humans. As reported by Sauer 
et al. [39] the detection of the 4’-carboxy metabolite in urine after ingestion of MPHP 
further implicates that oxidation is also the subsequent step in humans. 
The biotechnological approach described here was based on the biotechnological 
synthesis of the 4’-hydromethyl metabolite of another pyrrolidinophenone-type drug, 
MPBP, using the fission yeast strain CAD58 heterologously expressing human P450 
2D6 [33]. In the present work the fission yeast strains CAD64 and CAD66 
heterologously co-expressing P450 2D6, P450 2C19, respectively, and its redox 
partner hCPR were used [34]. P450 2D6 and 2C19 are among the most relevant in 
the metabolism of many therapeutic and illicit drugs in humans [16,26,36]. Previous 
studies on the metabolism of MPPP and MPHP show that both isozymes account for 
the vast majority of the formation of the respective 4’-hydroxymethyl metabolite, in 
case of MPPP even the only two CYP P450 isozymes found to be involved [46,51]. In 
the metabolism of MPPP, the main catalyzing isozyme according to these studies 
seems to be P450 2C19. The fact that in the present study a fission yeast strain only 
expressing P450 2D6 was used could be one reason why the parent drug MPPP was 
not metabolised completely during incubation. In the biotechnological synthesis of 
HO·MPHP CAD64 was preferred over CAD66, because it had shown higher 
conversion of MPHP to HO·MPHP and less formation of side products than the latter 
[34]. 
The metabolic pathways catalyzed by the isozymes and P450 2D6 and 2C19 
themselves are also of particular interest in pharmacologic and toxicological research 
for their polymorphically expression [16]. In so-called poor metabolizer subjects of 
these isozymes the hepatic clearance of drugs catalyzed by them can be significantly 
lower.  For P450 2D6 and 2C19 poor metabolizer subjects account for about 7% and 
3% of the Caucasian population, respectively [2,43]. Thus users of these drugs with 
poor metabolizer genotypes might stand at higher risk of developing adverse or toxic 
effects. However, further assessment of the clinical relevance of these genetic 
polymorphisms regarding the toxicokinetics of MPPP and MPHP would require 
clinical trials. This, however, seems at least problematic from an ethical point of view. 
Co-expression of the accessory protein hCPR generally enhances the activity of 
heterologously expressed human P450 enzymes [5,8,17,53]. Even though the 
  30 
presence of hCPR was obviously not critical in biotechnological synthesis of HO-
MPBP, this can not necessarily be expected for other substrates.  
The SPE procedure with a strong cation exchange extraction sorbent effectively 
retained the basic metabolite HO·MPHP as indicated by the very minor amounts in 
the supernatant after passing through the extraction cartridges. As described, in case 
of HO-MPPP there was a much higher loss of product. HO-MPPP and HO-MPHP 
were also effectively retained during the washing steps that however removed the 
vast majority of matrix compounds. In the final step, the retained compounds could 
be eluted with comparatively small volumes of elution solvent. The overall solvent 
consumption was considerably lower than in the back extraction described in the 
previous study of the biotechnological synthesis of HO-MPBP [33]. 
Because of formation of an unknown side product in the case of MPHP and 
incomplete removal of matrix compounds in both cases, the raw extract had to be 
cleaned up by semi-preparative HPLC. In the case of HO-MPPP this could be 
achieved by 32 injections with a run time of 15 min, for HO-MPHP even with a run 
time of 10 min, so that product cleanup could be completed in one work day in both 
cases.  
In a first attempt it was tried to isolate HO-MPPP from the collected HPLC fractions 
by SPE analogous to the method of solid-phase extraction from the fission yeast 
culture supernatant. But it proved too much loss of product due to competition of the 
metabolites with ammonium ions from the mobile phase buffer at the cation 
exchange sorbent. So for the further isolation of the metabolites HO-MPPP and HO-
MPHP from the collected HPLC fractions liquid-liquid extraction was preferably 
performed. 
Precipitation of the final product as hydrochloric salt was performed in the same 
way as previously described for HO·MPBP [33].  The final product yield of 14.8 % of 
HO-MPPP and 55 % of HO·MPHP seems to stand in contrast to the results of the in-
process control samples indicating effective solid-phase extraction, elution and liquid-
liquid extraction. However, in both cases it must be assumed that a considerable 
amount of product might have been separated with the fission yeast cells. These 
were not included in the workup to avoid interference from cell matrix compounds. A 
certain amount was probably also lost during HPLC cleanup and, most importantly, 
product precipitation. In addition, in case of MPPP the parent drug had not been 
completely metabolized so that after precipitation about 7.5 % of the amount of 
MPPP initially added to the fission yeast culture were still obtained. In any case, the 
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product yield of 55% in case of HO-MPHP is almost twice as high as the 30% that 
could have been expected with chemical synthesis according to the protocol 
described in the referred study [30]. Taking into account that only about 40 % of the 
initial MPPP were biotransformed to HO-MPPP, it can be assumed that the product 
yield really after extraction and purification process is 40 % of the theoretical 
maximum yield, which is still slightly more than the expected yield with chemical 
synthesis. Moreover, the 10 mg of HO-MPPP·HCl and the 42 mg of HO-MPHP·HCl 
obtained in the present study were sufficient for product characterization by GC-MS, 
NMR and HPLC-UV and for use as reference substance in further studies on MPPP 
and MPHP 4’-methyl hydroxylation in human organism. 
Concerning product identity, the fragmentation pattern and molecular mass of the 
trimethylsilylated products observed in GC-MS analysis and the signal shifts as 
compared to the parent drug in NMR analysis gave unambiguous proof that the 
isolated metabolites were indeed HO-MPPP and HO-MPHP. Concerning product 
purity, the fact that the peak area of HO-MPPP accounted for 93% of total peak area 
and that of HO-MPHP even for more than 99% of total peak area in HPLC analysis 
indicates the very high purity of the isolated products. This was further confirmed by 
the GC-MS data and the NMR data, which did not give any indication of relevant 
impurities. 
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5 CONCLUSION 
In conclusion, the presented data show that the biotechnological synthesis of 
HO-MPPP and HO-MPHP using fission yeast strains CAD64 and CAD66 co-
expressing human P450 2D6 and 2C19, respectively, and hCPR yielded the product 
in an acceptable amount and high purity. In comparison to classical chemical 
synthesis, the biotechnological approach was less time-consuming, less complicated 
and safer considering the mild reaction conditions and avoidance of hazardous 
chemicals and solvents. Biotechnological synthesis employing one of these new 
fission yeast strains may help overcome complicated and time-consuming chemical 
methods in the synthesis of drug metabolites. 
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7  ABBREVIATIONS  
PPP  α-pyrrolidinopropiophenone,  
1-phenyl-2-pyrrolidin-1-ylpropanone (IUPAC) 
PVP α-pyrrolidinovalerophenone,  
1-phenyl-2-pyrrolidin-1-ylpentanone (IUPAC) 
MPPP 4'-methyl-α-pyrrolidinopropiophenone,  
1-(4-methylphenyl)-2-pyrrolidin-1-ylpropan-1-one (IUPAC) 
HO-MPPP 4’-hydroxymethyl-α-pyrrolidinopropiophenone,  
1-(4-hydroxymethylphenyl)-2-pyrrolidin-1-ylpropan-1-one 
(IUPAC) 
MOPPP 4'-methoxy-α-pyrrolidinopropiophenone,  
1-(4-methoxyphenyl)-2-pyrrolidin-1-ylpropan-1-one (IUPAC) 
MDPPP 3',4'-methylenedioxy-α-pyrrolidinopropiophenone,  
1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylpropan-1-one 
(IUPAC) 
MDPV 3’,4’-methylenedioxypyrovalerone 
1-(3,4-methylenedioxyphenyl)-2-pyrrolidinylpentan-1-one 
(IUPAC) 
MPBP 4'-methyl-α-pyrrolidinobutyrophenone,  
1-(4-methylphenyl)-2-pyrrolidin-1-ylbutan-1-one (IUPAC) 
HO-MPBP 4’-methyl-α-pyrrolidinobutyrophenone, 
1-(-4-hydroxy-methylphenyl)-2-pyrrolidin-1-ylbutan-1-one 
(IUPAC) 
MPHP 4'-methyl-α-pyrrolidinohexanophenone,  
1-(4-methylphenyl)-2-pyrrolidin-1-ylhexan-1-one (IUPAC) 
HO-MPHP 4’-hydroxymethyl-α-pyrrolidinohexanophenone,  
1-(4-hydroxymethylphenyl)-2-pyrrolidin-1-ylhexan-1-one 
(IUPAC) 
hCPR Human Cytochrome P450 reductase 
GC-MS Gas Chromatographic-Mass Spectrometry 
MSTFA N-methyl-N-trimethylsilyl-trifluoroacetamide 
EMM Edinburgh minimal medium; 
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HP Hewlett Packard 
AT Agilent Technologies 
LLE Liquid-liquid Extraction 
SPE Solid-phase Extraction 
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